Table II.
Characteristics of Subjects With SCID Who Underwent Hematopoietic Stem Cell Transplantation
| Early Transplantation (<3.5 months) (n=7) |
Late Transplantation (≥3.5 months) (n=13) |
|
|---|---|---|
| Study site | ||
| California | 2 | 0 |
| Florida | 1 | 5 |
| Pennsylvania | 4 | 8 |
| SCID type | ||
| XSCID | 3 | 5 |
| Jak3 | 0 | 1 |
| IL-7rα | 1 | 0 |
| Omenn | 1 | 1 |
| ADA | 0 | 2 |
| Artemis | 0 | 1 |
| Unknown | 2 | 3 |
| Outcomes | ||
| Death before transplantation | 0 | 1 |
| Complications | 4 | 8 |
| Alive and well | 3 | 3 |
| Death after transplantation | 0 | 1 |
| Admitted at outside hospital before diagnosis | 0 | 11 |
| Insurance type | ||
| Private | 2 | 7 |
| Government subsidized | 3 | 6 |
| Other/unknown | 2 | 0 |
| Average number of hospital days billed | 63.4 | 113.2 |
| Average charges/diagnosis to transplant | $101,385.13* | $864,774.67** |
| Average charges/transplant to 180 days | $211,597.46 | $904,797.93** |
| Average total charges | $365,784.89 | $1,458,045.90** |
| Average total charges per day billed | $5,769.47 | $12,880.25 |
ADA=adenosine deaminase; IL-7ra=interleukin-7 receptor α; Jak3=Janus kinase 3; SCID=severe combined immunodeficiency; XSCID=X-linked severe combined immunodeficiency.
*
Early: average charges dx-tx calculated for n=6 instead of 7 (only post tx charges applied in 1 case)
**
Late: average total charges calculated for n=13 (total cases); charges dx-tx calculated for n=8 (2 referred in for transplant only, and 1 patient died before transplant; previous charges incurred at an outside hospital for all 3 of these as well); average charges tx-180d calculated for n=12 because 1 patient died before transplant.